Solara Active Pharma Sciences liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

3.43×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.96×	0.96×	0.77×	0.63×	1.08×
0.60×	0.60×	0.44×	0.34×	0.57×
25.1	7.5	4.0	8.4	8.7
243	−35.8	−215	−455	86.4

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SOLARA₹653.80

Solara Active Pharma Sciences Limited

· Pharma & Health

₹ CrorePeersINDSWFTLAB DCAL SMSPHARMA HIKAL PANACEABIO SAIPARENT INDOCO UNICHEMLABMcap ₹2,910 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	3.43
Current Ratio	1.08	0.63	0.77	0.96	0.96
Quick Ratio	0.57	0.34	0.44	0.60	0.60
Cash, Equiv & ST Investments	8.7	8.4	4.0	7.5	25.1
Working Capital	86.4	-454.7	-215.4	-35.8	243.0

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.